TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced preliminary results from its Phase II “Neuracept” trial for EpiCept™ NP-1 Cream in patients suffering from diabetic peripheral neuropathy (DPN). All pain scores measured trended in favor of the NP-1 treated patients over the placebo group, indicative of an analgesic effect in this type of peripheral neuropathic pain. EpiCept has concluded that preliminary data derived from the trial support the continued study of NP-1 in a late-stage pivotal clinical trial.
